Chlorhexidine - GlaxoSmithKline

Drug Profile

Chlorhexidine - GlaxoSmithKline

Alternative Names: Clorhexidine gel - GlaxoSmithKline; Umbipro

Latest Information Update: 04 May 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Anti-infectives; Antiseptics; Biguanides; Small molecules
  • Mechanism of Action Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Infections

Most Recent Events

  • 29 Apr 2016 The Committee for Medicinal Products for Human Use recommends approval (under Article 58 procedure) of Chlorhexidine gel (7.1% chlorhexidine digluconate gel, equivalent to 4% chlorhexidine) for Infections (in neonates) in markets outside EU
  • 16 Oct 2015 Phase-III clinical trials in Infections (In neonates) in Nepal (Topical) before October 2015 (GSK pipeline, March 2015)
  • 12 Oct 2015 Preregistration for Infections (In neonates) in European Union (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top